How the pharma company got a better understanding of the impact recently approved competitors would have on both its established brands and its pipeline therapy.
Why the pharma company identified critical gaps in its existing real-world evidence, leading it to expand data collection in phase III trials.
How the pharma company also used P&T Perspectives insights to create a competitive pricing strategy for its new therapy.